The potassium channel-blocking agent fampridine (4-Aminopyridine), especially its slow-release formulation (Fampyra®), is generally a safe drug with well-studied pharmacokinetic properties [49] and approved for the symptomatic improvement of walking in MS [44]. This evidence concerns the gene KCNA3 and myeloid sarcoma.